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Abstract
Background: There are few data on factors influencing human papillomavirus (HPV) vaccination uptake in sub-Saharan
Africa. We examined the characteristics of receivers and non-receivers of HPV vaccination in Tanzania and identified reasons
for not receiving the vaccine.
Methods: We conducted a case control study of HPV vaccine receivers and non-receivers within a phase IV cluster-
randomised trial of HPV vaccination in 134 primary schools in Tanzania. Girls who failed to receive vaccine (pupil cases) and
their parents/guardians (adult cases) and girls who received dose 1 (pupil controls) of the quadrivalent vaccine (GardasilTM)
and their parents/guardians (adult controls) were enrolled from 39 schools in a 1:1 ratio and interviewed about cervical
cancer, HPV vaccine knowledge and reasons why they might have received or not received the vaccine. Conditional logistic
regression was used to determine factors independently associated with not receiving HPV vaccine.
Results: We interviewed 159 pupil/adult cases and 245 pupil/adult controls. Adult-factors independently associated with a
daughter being a case were older age, owning fewer household items, not attending a school meeting about HPV vaccine,
and not knowing anyone with cancer. Pupil-factors for being a case included having a non-positive opinion about the
school de-worming programme, poor knowledge about the location of the cervix, and not knowing that a vaccine could
prevent cervical cancer. Reasons for actively refusing vaccination included concerns about side effects and infertility. Most
adult and pupil cases reported that they would accept the HPV vaccine if it were offered again (97% and 93% respectively).
Conclusions: Sensitisation messages, especially targeted at older and poorer parents, knowledge retention and parent
meetings are critical for vaccine acceptance in Tanzania. Vaccine side effects and fertility concerns should be addressed prior
to a national vaccination program. Parents and pupils who initially decline vaccination should be given an opportunity to
reconsider their decision.
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Introduction
Infection with human papillomavirus (HPV) is the primary
cause of cervical cancer, with approximately 70% of cases caused
by HPV genotypes 16 and 18 [1,2]. Tanzania has one of the
highest rates of cervical cancer and mortality from cervical cancer
in the world [3]. Two HPV vaccines offer a new opportunity for
primary prevention. The vaccines protect against HPV type 16
and 18 infections and associated cervical pre-cancerous lesions
and, in the case of the quadrivalent vaccine, also against HPV 6
and 11, the main cause of genital warts [4,5,6]. Vaccination is
typically targeted at young adolescent or pre-adolescent girls
before they can acquire HPV after sexual debut [7]. This is not an
age group that is routinely targeted by vaccination programmes in
developing countries. Parental and community acceptability of a
vaccine that prevents a sexually transmitted infection and how the
vaccine is promoted and delivered by health-care providers will
influence its uptake and vaccine effectiveness [8,9,10,11]. To
inform policy makers on the best delivery strategies and
sensitisation messages needed when a new vaccination programme
is commenced, it is important to understand factors that influence
the decision to receive or not receive the vaccine
As part of a project to demonstrate the feasibility, acceptability
and costs of delivering HPV vaccine in primary schools in
Tanzania, we examined the characteristics of receivers and non-
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receivers of HPV vaccination and reasons for receiving or not
receiving the vaccine.
Materials and Methods
Ethical considerations
Ethical approval was provided by the ethical committees of the
Medical Research Coordinating Committee, Tanzania, and the
London School of Hygiene and Tropical Medicine.
HPV vaccination project activities
A phase IV cluster-randomised trial (NCT01173900) was
conducted in Tanzania to compare two different vaccine delivery
strategies in primary schools; age-based delivery, where the
quadrivalent HPV vaccine, GardasilTM, was offered to all girls
in the school who were born in 1998, and a class-based strategy
where girls who were enrolled in primary school class 6 in 2010
were offered vaccination [12]. The trial was conducted between
August 2010 and June 2011 and was located in Mwanza city and
in ten administrative units (wards) of neighbouring Misungwi
district.
In total 134 schools were randomly selected from 241 primary
schools; 67 were randomised to the age-based strategy and 67 to
the school-based strategy.
Three vaccine doses were offered to eligible girls during four
rounds of school visits over 11 months. Dose 1 was offered over
two rounds, with girls who missed dose 1 the first time being
offered another opportunity to receive this during the second
round of vaccination. If girls missed a dose at school, the vaccine
was made available at the health facility for a period of two to four
weeks after the school visit but was not left at the health facility
permanently because of cold storage space limitations. Teachers
were provided with a list of pupils who had missed their booked
dose and asked to encourage them to attend the health facility.
Social mobilisation was conducted through parent-teacher
meetings, letters to parents, meetings with ward and other
community leaders and religious leaders, distribution of project
leaflets, radio broadcasts and performances by community dance
and drama troupes. The project adopted an opt-out consent
approach for parents following consultation with key stakeholders.
When information about the date of vaccination in schools was
provided to parents through letters delivered by their daughters,
they were asked to indicate to teachers or the project team if they
did not wish their daughter to be vaccinated or to keep them back
from school.
Selection of cases and controls
To determine factors associated with not being vaccinated, we
conducted a case control study on a sample of 250 girls who did
not receive dose 1 (cases) and 250 girls who received dose 1
(controls). For each of the 250 cases and 250 controls, we aimed to
interview both the girl and her parent/guardian. Non-receivers
were girls who were eligible for vaccination but did not receive
dose 1, either because they were absent from school or were
reported by the teacher to be ill or their parents or the girl
indicated that they did not wish to be vaccinated or the girl
absconded from school on the vaccination day. Eligible girls who
wished to be vaccinated but did not receive dose 1 because of
suspected pregnancy, or because the study team judged them to be
too unwell, were excluded from the case-control study.
Cases and controls were matched on school. In each of the
selected schools (described below), we invited for interview all girls
who did not receive dose 1 (either at school or at the health facility)
and who were eligible to be included as cases, and an equal
number of randomly-selected girls who received dose 1 as controls.
For each school, a list of replacement control pupils was drawn up
in the event that a control pupil or parent refused to participate in
the interviews. No replacements were possible for cases within
each school, since all non-receivers were invited.
Sample size and power
To achieve the target sample size of approximately 250 parent-
child cases and 250 parent-child controls, we selected a random
sample of 2 private schools, 15 government urban schools and 22
government rural schools, from those schools where there was at
least one potential case and one potential control (Table 1). We
aimed to interview 7 parent-child cases in the private schools, and
123 parent-child cases each from the government urban and rural
schools. Schools in which all eligible girls were vaccinated (N= 27)
were excluded from the case-control study since there were no
cases at these schools. Similarly, 4 schools in which all eligible girls
failed to be vaccinated were excluded. The decision to include 39
schools was based on the number of schools needed to obtain
approximately 250 cases if all non-receivers were invited to take
part in each of these schools.
The study was powered to provide $80% power to detect an
odds ratio (OR) of 1.75 for risk factors associated with not
receiving the vaccine, assuming that the prevalence of the risk
factor in the controls was between 25–65%, or 90% power for an
OR of 2.00, assuming that the prevalence of the risk factor was
between 20–70%.
Enrolment and interview procedures
An interviewer visited the girl’s household to ask for written or
witnessed oral (if illiterate) parental/guardian consent for an
interview with the parent/guardian and a separate face-to-face
interview with their daughter/ward. Written informed assent of
the eligible girl was sought separately once parental consent had
been given.
Using pre-tested structured questionnaires, the interviewer
collected quantitative data on sociodemographic information,
health-seeking behaviour, especially in relation to vaccinations,
knowledge about cervical cancer, and the HPV vaccine. Closed
and open-ended questions on reasons for receiving or not receiving
vaccination were asked at the end of the questionnaire and, apart
from these, all other questions were identical for cases and
controls. The child was interviewed separately from the partici-
pating adult. Some open-ended questions were also asked about
satisfaction with the original decision to receive or not receive
vaccination.
Statistical considerations
Data were double-entered in OpenClinica 3.0.1 (2009; Akaza
Research; Waltham, Massachusetts, USA) and analyzed in
STATA 11.0 (StataCorp LP; College Station, Texas, USA).
We estimated odds ratios (OR) and 95% confidence intervals
(CI) for factors associated with not receiving vaccine, using
conditional logistic regression to account for clustering within
schools. Potential determinants of not being vaccinated were
examined using a conceptual framework with three levels: socio-
economic, health-seeking behaviour, and knowledge of the HPV
vaccine project. Parents’ age was included in all models a priori.
Socio-economic factors that were associated with not receiving
vaccine at p,0.10 were included in a multivariable model and
those independently associated at p,0.10 were retained in a core
model. Health-seeking factors were added to this core model one
by one. Those associated with not receiving vaccine at p,0.10,
after adjusting for socio-economic factors, were included in a
Case Control Study: HPV Vaccine Uptake in Tanzania
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multivariable model and retained if they remained associated at
p,0.10. Associations with knowledge of the HPV vaccine project
were determined in a similar way. The final model excluded
factors one at a time until all remaining factors were associated at
the p,0.05 level.
Girls who did not receive the vaccine comprised two potentially
different groups: those who were absent on the day of vaccination,
but who may have wanted the vaccine, and those who attended
but actively refused vaccination. We did not collect data on
reasons for absence, so we could not distinguish between absence
to avoid vaccination and absence for other reasons. However, we
did an additional analysis to compare the characteristics of girls
who were absent with those who refused vaccination, using a
Pearson chi-squared test with the second-order correction of Rao
and Scott to account for the clustered design.
Results
Vaccine coverage
Vaccine coverage results have been described previously
[12,13]. In summary, 4684/5532 (84.7%) of eligible girls enrolled
in the 134 schools received dose 1; 86.4% in standard-based
schools compared with 82% in age-based schools (p = 0.30).
Enrolment and interviewees
From 252 eligible cases in the 39 randomly selected schools, we
were able to locate, enrol and interview 159 (63.1%) girls (‘‘pupil
cases’’) and 168 (66.7%) parents/guardians (‘‘adult cases’’,
Table 1). Nine girls whose parents consented were not interviewed:
5 had moved to an unknown address, 1 was at boarding school,
the parent withdrew consent for one girl, and 2 had a disability
which precluded the interview. Analysis of cases was restricted to
the 159 pupil/adult case pairs in 35 schools.
From the 254 randomly selected controls in the same 39
schools, we located, enrolled and interviewed 211 (83.1%) pupils
(‘‘pupil controls’’) and 211 (83.1%) parents/guardians (‘‘adult
controls’’). Of these, one adult control did not have a matching
pupil interview because the girl had moved away, while one pupil
control did not have matching adult data because the parent
questionnaire could not be located. A further 40 adult/pupil
control pairs were enrolled from a list of replacement controls.
Five pupil/adult control pairs from four schools were not included
in the analysis because there were no matching cases at those
schools. Analysis of controls was restricted to the remaining 245
pupil controls and adult controls in 35 schools.
Over half of the adults interviewed were mothers (Table 2). The
median age of adult interviewees was 40 (IQR 34–49) for adult
cases and 37 (IQR 32–45) for adult controls; 67% of adult cases
and 77% of adult controls were married. No education was
reported by 16% of adult cases and 9% of adult controls. Only
13% of cases and 17% of controls owned five or more of listed
household items (radio, cell-phone, television, bicycle, motorbike,
car, livestock or a plot of land); 6% of adult cases and 1% of adult
controls owned none of these items.
Not all adults were aware of whether their respective daughters/
wards had received the vaccine. Of the 159 adult cases, 109 (68%)
believed that the pupil had not received the vaccine, 9 (6%)
thought that she had received it, and 41 (26%) did not know. Of
the 245 adult controls, 196 (80%) believed that the pupil had
received the vaccine, 14 (6%) thought that she had not received it,
and 35 (14%) did not know.
The median age of interviewed pupils was 13 years (IQR 13–15
years) for cases and 13 years (IQR 13–15) for controls. Overall
19% of cases and 10% of controls reported frequently being absent
from school (Table 3).
Factors associated with not receiving the vaccine
From project and teacher records, 85 (53%) of 159 cases did not
receive dose 1 of vaccine because the pupil was absent from school
on the vaccination day, 70 (44%) because a parent refused, 2 (1%)
because the girl refused and 2 (1%) for other reasons. Amongst
cases, more parents in the ‘‘absent from school’’ group had
Table 1. Selection, participation and analysis of cases and controls.
Govt rural schools
(N=22)
Govt urban schools
(N=15) Private schools (N=2) All schools (N=39)
Cases Controls Cases Controls Cases Controls Cases Controls
Initially selected 123 125 122 122 7 7 252 254
Girls
Interviewed from initial selection 73 109 83 96 3 6 159 211
Interviewed from replacement list - 14 - 25 - 1 - 40
Dropped because no adult questionnaire 0 1 0 0 0 0 0 1
Dropped because no cases interviewed at
school
- 2 - 2 - 1 - 5
Adults
Interviewed from initial selection 81 109 84 96 3 6 168 211
Interviewed from replacement list - 14 - 25 - 1 - 40
Dropped because no girl questionnaire 8 1 1 0 0 0 9 1
Dropped because no cases interviewed at
school
- 2 - 2 - 1 - 5
Total parent-girl pairs analysed 73 120 83 119 3 6 159 245
Age-based 42 67 8 15 3 6 53 88
Standard (class) based 31 53 75 104 0 0 106 157
doi:10.1371/journal.pone.0045231.t001
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Table 2. Univariate analysis of factors associated with girls not receiving HPV vaccine: characteristics of parents/guardians.
Cases (N=159) Controls (N=245) Unadjusted OR [95% CI]1
N % N %
SOCIO-DEMOGRAPHIC FACTORS
Relationship to girl P= 0.58
Mother 90 56.6 131 53.5 1
Father 28 17.6 36 14.7 1.05 [0.59, 1.86]
Other female relative 32 20.1 62 25.3 0.73 [0.44, 1.22]
Other male relative 9 5.7 16 6.5 0.74 [0.31, 1.77]
Age (years) P= 0.08
,30 12 7.5 31 12.6 1
30–39 64 40.3 112 45.7 1.60 [0.76, 3.38]
40–49 42 26.4 63 25.7 1.80 [0.82, 3.97]
50+ 35 22.0 32 13.1 3.12 [1.35, 7.23]
Age not known 6 3.8 7 2.9 2.46 [0.64, 9.45]
Highest level of education P= 0.09
Secondary/higher 15 9.4 33 13.5 1
Primary 119 74.9 189 77.1 1.34 [0.68, 2.62]
None 25 15.7 23 9.4 2.44 [1.03, 5.79]
Marital status P= 0.006
Married 107 67.3 189 77.1 1
Divorced/separated/widowed 43 27.0 37 15.1 2.22 [1.33, 3.71]
Single 9 5.7 19 7.8 0.85 [0.36, 1.98]
Occupation (highest in household) P= 0.25
At least one professional/business 63 39.6 113 46.1 1
No professional/business 96 60.4 132 53.9 1.30 [0.83, 2.04]
Religion P= 0.32
Christian 129 81.1 206 84.1 1
Other/none 30 18.9 39 15.9 1.33 [0.76, 2.33]
Number of items owned2 P= 0.004
5 or more 21 13.2 42 17.2 1
2–4 110 69.2 174 71.0 1.49 [0.82,2.72]
1 19 11.9 27 11.0 1.62 [0.71,3.70]
0 9 5.7 2 0.8 15.98 [2.92,87.55]
Number of children P= 0.16
1–3 38 23.9 79 32.2 1
4–6 78 49.1 112 45.7 1.52 [0.94, 2.47]
. 6 43 27.0 54 22.1 1.62 [0.90, 2.91]
HEALTH SEEKING BEHAVIOUR
Girl treated by de-worming programme P= 0.06
Yes 79 49.7 146 59.6 1
No 80 50.3 99 40.4 1.47 [0.98, 2.24]
Adult’s opinion of de-worming programme P= 0.03
Good 101 63.5 183 74.7 1
Did not like/no opinion 58 36.5 62 25.3 1.64 [1.06, 2.54]
Adult’s trust in government health institutions P= 0.55
Trust 148 93.1 225 91.8 1
Little/no trust/don’t know 11 6.9 20 8.2 0.79 [0.37, 1.71]
Girl immunised at MCH clinic P= 0.79
Yes – all immunisations 125 78.6 199 81.2 1
Yes – some immunisations 17 10.7 22 9.0 1.27 [0.64, 2.53]
No immunizations/don’t know 17 10.7 24 9.8 1.08 [0.55, 2.13]
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received no education compared with the ‘‘school, attender/
refuser’’ group (20% vs. 8% respectively; p = 0.003) and there was
a higher proportion of parent cases in the ‘‘absent’’ group who
heard about the vaccine through a non-project source than in the
‘‘attender/refuser’’ group (78% vs. 57%; p= 0.008). Pupils in the
‘‘absent’’ group were older than in the ‘‘refuser’’ group (28% aged
15–16 vs. 6%, respectively; p = 0.004). There were no other
significant differences between these groups.
In the unadjusted analysis, adult-reported factors associated
with the pupil being a case included being divorced, separated or
widowed, owning fewer household items, not having attended a
teacher-parent meeting to discuss the cervical cancer vaccine,
having a non-positive opinion of the school de-worming
programme and not knowing anyone who had had cancer
(Table 2). Increasing age, lower education, hearing about the
vaccine from a non-project source, the pupil not being treated by
the de-worming programme, and the adult not being immunised
in childhood were weakly associated with the pupil not receiving
HPV vaccine. Having little or no trust in government health
institutions was not significantly associated with being unvacci-
nated.
Pupil-reported factors associated with being a case in the
unadjusted analysis included age, ever being absent from school,
first hearing about the HPV vaccine from a non-project source,
not attending a school meeting to discuss the vaccine, not having
been treated by the de-worming programme, not having a positive
opinion (i.e. no opinion or did not like) of the de-worming
programme, not knowing the location of the cervix in the body,
not knowing the cause of cervical cancer and not mentioning
vaccine as a method to prevent cervical cancer (Table 3). Not
having received other vaccinations (e.g. tetanus toxoid) at school
had a borderline association with being a case. Having passed
sexual debut was not associated with being unvaccinated. On
multivariable analysis (Table 4), adult factors that were indepen-
dently associated with the pupil being unvaccinated were
increasing age (adjusted OR (aOR) 3.62; 95%CI 1.39–9.58 for
those $50 years compared with those ,30 years), owning fewer
household items (aOR 12.71; 95%CI 2.11–76.75 for not owing
any of selected household items), not attending a school meeting
about the HPV vaccine project (aOR 2.31; 95%CI 1.34–3.98) and
not knowing anyone with cancer (aOR 2.12; 95%CI 1.28–3.49).
Pupil-reported factors that were independently associated with not
having received the vaccine were having a non-positive opinion
about the school de-worming programme (aOR 1.92; 95%CI
1.14–3.23), poor knowledge about location of the cervix (aOR
2.65; 95%CI 1.17–6.01 for somewhere in reproductive system;
aOR 3.37; 95%CI 1.62–6.99 for not known or somewhere in the
abdomen or elsewhere in the body), and not knowing that a
vaccine could prevent cervical cancer (aOR 2,73; 95%CI 0.91–
8.13 for mentioning screening, condoms or no sex; aOR 1.78;
95%CI 1.04–3.06 for not known or methods excluding vaccina-
tion, screening, condoms or no sex).
Adult and pupil reasons for receiving or not receiving
vaccination
Cases and controls were asked why they had or had not received
vaccination. Multiple answers were allowed. Although controls
and cases were selected from vaccine records, 58 (20%) adult
controls stated that they thought their daughters had not received
vaccine. Among the 196 adult controls who reported that their
daughter had received vaccine, their reasons for accepting
vaccination (Table 5) included protection against cervical cancer
(N= 175; 89%), health benefits (N= 43; 22%), knowing someone
who had had cancer (N= 25; 13%) and encouragement by the
project team (N=19; 10%). Only 6 (3%) were not happy with
their decision, citing a lack of consultation/information and
concern over side effects.
Reasons for being vaccinated, as reported by 224 (91%) of 245
pupil controls, included protection from cervical cancer (N= 225;
91%), health benefits (N= 57; 24%), and parental wishes (N= 52;
21%; Table 5). Only one girl was unhappy with the decision to be
vaccinated, explaining that she felt under pressure to receive the
vaccine. It was not clear whether this pressure came from parents,
teachers, fellow pupils or the vaccine team.
Of the 159 adult cases, 109 (69%) reported that their daughters
were not vaccinated. Reasons for not agreeing to vaccination
Table 2. Cont.
Cases (N=159) Controls (N=245) Unadjusted OR [95% CI]1
N % N %
Adult immunised in childhood P= 0.008
Yes 103 64.8 190 77.6 1
No 56 35.2 55 22.4 1.82 [1.17, 2.85]
KNOWLEDGE AND ATTITUDES
Adult’s first awareness of HPV vaccine P= 0.08
Through project source 50 31.4 95 38.8 1
Through non-project source 109 68.6 150 61.2 1.49 [0.95, 2.32]
Adult attended meeting to discuss vaccine P= 0.002
Yes 36 22.6 88 35.9 1
No 123 77.4 157 64.1 2.11 [1.32, 3.39]
Adult known anyone made ill/died from cancer P,0.001
Yes 79 49.7 163 66.5 1
No 80 50.3 82 33.5 2.17 [1.40, 3.36]
1Odds ratios are calculated from conditional logistic regression (conditioned on school).
2Possible items owned are : radio; cellphone; television; bicycle; motorcycle; car; live-stock; agricultural plot.
doi:10.1371/journal.pone.0045231.t002
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Table 3. Univariate analysis of factors associated with girls not receiving HPV vaccine: characteristics of girls.
Cases (N=159) Controls (N=245) Unadjusted OR [95% CI]1
N % N %
SOCIO-DEMOGRAPHIC FACTORS
Age of girl (years)(N =263)2 P= 0.02
#12 6 5.7 18 11.5 1
13–14 66 62.3 72 45.9 3.10 [1.12, 8.59]
15–16 22 20.7 53 33.8 1.47 [0.48, 4.52]
$17 12 11.3 14 8.9 3.37 [0.91, 12.41]
Girl’s class (standard)(N =141)3 P= 0.54
Class 3 5 9.4 10 11.4 1
Class 4 8 15.1 17 19.3 1.21 [0.25, 5.90]
Class 5 19 35.9 38 43.2 1.23 [0.30, 5.14]
Class 6 21 39.6 23 26.1 2.14 [0.48, 9.61]
Girl ever absent from school P= 0.04
Never 66 41.5 110 44.9 1
Occasionally 63 39.6 110 44.9 1.02 [0.64, 1.61]
Sometimes/frequently 30 18.9 25 10.2 2.19 [1.15, 4.18]
HEALTH SEEKING BEHAVIOUR
Girl received other vaccinations at school P= 0.08
Yes 40 25.2 45 18.4 1
No 119 74.8 200 81.6 0.64 [0.39, 1.05]
Girl treated by de-worming programme P= 0.002
Yes 93 58.5 176 71.8 1
No 66 41.5 69 28.2 2.00 [1.29, 3.12]
Girl’s opinion of de-worming programme P,0.001
Good 91 57.2 185 75.5 1
No opinion/did not like 68 42.8 60 24.5 2.60 [1,66, 4.08]
Girl’s source of treatment when ill P= 0.79
Government clinic/hospital 114 71.7 173 70.6 1
Private clinic/hospital/pharmacy 45 28.3 72 29.4 0.94 [0.59, 1.50]
KNOWLEDGE AND ATTITUDES
Girl’s first awareness of HPV vaccine P,0.001
Through project source 140 88.1 243 99.2 1
Through non-project source 19 11.9 2 0.8 17.61 [4.00, 77.62]
Girl attended meeting to discuss vaccine P= 0.001
Yes 42 26.4 99 40.4 1
No 117 73.6 146 59.6 2.05 [1.31, 3.21]
Girl known anyone with cervical cancer P= 0.74
Yes 3 1.9 5 2.0 1
No 156 98.1 240 98.0 1.27 [0.30, 5.48]
Girl’s knowledge of location of cervix P,0.001
Top of vagina 16 10.1 64 26.1 1
In uterus/reproductive system 28 17.6 62 25.3 2.03 [0.96, 4.30]
Abdomen/another part/don’t know 115 72.3 119 48.6 3.99 [2.10, 7.58]
Girl’s knowledge of cause of cervical cancer P= 0.01
Correct/partially correct answer 8 5.0 30 12.2 1
Incorrect answer 151 95.0 215 87.8 2.59 [1.15, 5.85]
Girl’s knowledge of cervical cancer prevention P,0.001
Vaccine specifically mentioned 84 52.8 182 74.3 1
No mention of vaccine, but any of screening or condom use or no sex 9 5.7 10 4.1 2.12 [0.82, 5.49]
Other, not including any of those above 66 41.5 53 21.6 2.67 [1.69, 4.23]
Case Control Study: HPV Vaccine Uptake in Tanzania
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included concern over either side effects (N= 44; 40%) or
infertility (N=22; 23%), or insufficient knowledge about the
vaccine (N=24; 22%; Table 5). Twenty-three (21%) had wanted
their daughter/ward to receive the vaccine but the girl had been
absent from school on the vaccination day. Overall 77 (71%)
regretted their decision, of whom 52 (68) stated that the girl had
missed receiving the protection conferred by vaccination, and 17
(22%) that they had not understood the value of the vaccine. Most
(N= 75; 97%) said they would agree to the vaccination if it were
offered again because the vaccine would protect their daughters/
wards from cervical cancer (N= 60; 80%), and that the vaccine
was safe (N= 43; 57%).
Overall 153/159 (96%) pupil cases reported that they had not
been vaccinated, of whom 50 (33%) stated that they had been
absent from school on the vaccination day, 37 (24%) that both
parents had refused permission for the vaccination, 34 (22%) had
Table 3. Cont.
Cases (N=159) Controls (N=245) Unadjusted OR [95% CI]1
N % N %
Girl ever had sexual intercourse P= 0.14
Yes 11 6.9 10 4.1 1
No 148 93.1 235 95.9 0.50 [0.20, 1.26]
1Odds ratios are calculated from conditional logistic regression.
2Girl’s age is based on schools with standard-based vaccination strategy only.
3Girl’s standard is based on schools with age-based vaccination strategy only.
doi:10.1371/journal.pone.0045231.t003
Table 4. Multivariate analysis of factors independently associated with girl not receiving HPV vaccine.
Adjusted OR [95% CI]1
Age of adult interviewee (years) P= 0.03
,30 1
30–39 1.32 [0.57, 3.09]
40–49 1.97 [0.81, 4.79]
50+ 3.62 [1.37, 9.58]
Age not known 2.16 [0.45, 10.48]
Number of items owned by adult P= 0.02
5 or more 1
2–4 1.47 [0.73, 2.94]
1 2.11 [0.81, 5.45]
0 12.71 [2.11, 76.75]
Adult known of anyone made ill by/died from cancer P= 0.003
Yes 1
No 2.12 [1.28, 3.49]
Adult attended teacher/parent meeting to discuss vaccine P= 0.002
Yes 1
No 2.31 [1.34, 3.98]
Girl’s opinion of deworming programme P= 0.01
Good 1
No opinion/did not like 1.92 [1.14, 3.23]
Girl’s knowledge of location of cervix P= 0.003
Top of vagina 1
In uterus/reproductive system 2.65 [1.17, 6.01]
Abdomen/another part/don’t know 3.37 [1.62, 6.99]
Girl’s knowledge of cervical cancer prevention P= 0.03
Vaccine specifically mentioned 1
No mention of vaccine, but any of screening or using condoms or no sex 2.73 [0.91, 8.13]
Other, not including any of those above 1.78 [1.04, 3.06]
1Exposures are adjusted for all other potential risk-factors in the model. Odds ratios are calculated from conditional logistic regression.
doi:10.1371/journal.pone.0045231.t004
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concerns about side effects, 25 (16%) were afraid of injections, and
20 (13%) had infertility concerns (Table 5). In total 114 (75%) girls
were unhappy about not receiving the vaccine, 102 (89%) feeling
they had missed an opportunity to protect their health and 9 (8%)
stating they had been forbidden by their parents to get vaccinated
or were misled about side-effects. Of these 106 (93%) said that they
would accept vaccination if given another opportunity to have this
because it offered protection against cancer (N=85; 80%), the
vaccine was safe (N= 38; 36%), their friends had had it (N= 16;
15%) or that their parents would like them to receive it (N= 10;
9%).
Discussion
This is the first case control study exploring individual-level
factors associated with not receiving HPV vaccination in a
developing country. HPV vaccination in the first HPV vaccine
delivery project in Tanzania had high acceptance, with over 80%
of girls receiving at least one dose of vaccine [12,13]. With the
announcement of Tanzania’s plans to launch a national HPV
vaccination programme in 2012–2013, it is essential to explore
factors associated with receipt or non-receipt of vaccine.
Our main findings suggest that several important programmatic
factors will be critical to reassure parents/guardians that HPV
vaccine is safe and effective. These include parental attendance at
school meetings and ensuring that girls have attended education
and information sessions and retain messages about cervical
cancer and the vaccine. Girls whose parents/guardians did not
attend a school sensitisation meeting or girls who could not name
basic factors related to the cervix and to HPV vaccine as a
prevention method for cervical cancer were at high risk of not
being vaccinated. Sensitisation messages will, however, need to be
tailored to the target population. One study in the US has shown
that provision of information through leaflets improved knowledge
but was not sufficient to ensure pre-vaccination parental accept-
ability and concluded that attitudes and life experiences were more
influential in determining HPV vaccine acceptance [11]. Other
studies in the US found that recommendations from doctors
influenced actual acceptance of HPV vaccine [14,15]. In our
setting, face-to-face meetings with teachers and health workers
which allowed questions and concerns to be answered, and
government endorsement of the vaccine as well as knowing
someone with cancer probably all contributed to actual parental
acceptance [16].
Parents/guardians from poorer households with few modern or
desired traditional material possessions had a high risk of not
having their daughters vaccinated. Poverty has been associated
Table 5. Parent/guardian and pupil satisfaction with decision to accept or refuse HPV vaccination.
Controls N (%) Cases N (%)
Parent/guardians1 196 Parent/guardians2 109
Happy with decision to vaccinate 190 (96.9) Happy with decision not to vaccinate 32 (29.4)
Reasons for satisfaction with decision Reasons for satisfaction with decision
Will provide protection against cervical cancer 55 (28.9) Concern over side effects 8 (25.0)
Will provide protection against cancer 19 (10.0) Concern over infertility 8 (25.0)
Will provide general protection 99 (52.1) Unspecified worries 7 (21.9)
Vaccine safety/absence of side-effects 6 (3.2) Other reason 9 (28.1)
Other reason 11 (5.8)
Unhappy with decision to vaccinate 6 (3.1) Unhappy with decision not to vaccinate 77 (70.6)
Reasons for dissatisfaction with decision Reasons for dissatisfaction with decision
Lack of consultation/awareness 3 (50.0) Girl missed having protection of vaccine 52 (67.5)
Concern over side-effects 2 (3.3) Did not understand value of vaccine/insufficient information 17 (22.1)
Other reason 1 (16.7) Other/no reason 8 (10.4)
Pupils 245 Pupils3 153
Happy with decision to be vaccinated 244 (99.6) Happy with decision not to be vaccinated 39 (25.6)
Reasons for satisfaction with decision Reasons for satisfaction with decision
Protection against cervical cancer 159 (65.1) Avoided side effects of vaccine 7 (17.9)
Protection against disease 51 (20.9) Fear of injections 7 (17.9)
General benefit 28 (11.5) Fear of infertility/reproductive problems 3 (7.7)
No reason 6 (2.5) Prevented by/obeyed parent(s) 10 (25.6)
Other/no reason 12 (30.8)
Unhappy with decision not to be vaccinated 1 (0.4) Unhappy with decision not to vaccinate 114 (74.4)
Reasons for dissatisfaction with decision Reasons for dissatisfaction with decision
Felt pressurized to be vaccinated 1 (100) Missed protection offered by vaccination 102 (89.5)
Obeyed parents/felt mislead 9 (7.9)
Other/no reason 3 (2.6)
1196/245 (80%) adult controls who reported during interviews that daughter/ward had received vaccine.
2109 of 159 (69%) adult cases who reported during interview that daughter/ward had not received vaccine.
3153 of 159 (96%) pupil cases who reported during interview that they had not received vaccine.
doi:10.1371/journal.pone.0045231.t005
Case Control Study: HPV Vaccine Uptake in Tanzania
PLOS ONE | www.plosone.org 8 October 2012 | Volume 7 | Issue 10 | e45231
with poorer completion rates of HPV vaccination in the US [17].
Reasons for this are unknown but may be related to poor
education, a lack of understanding of the benefits of health
interventions within the household and/or poor health seeking
behaviours or a preference for ‘‘traditional’’ forms of health care.
Older adult interviewees were also associated with poor vaccine
uptake. Older household members may not have been the parents
of eligible girls and may therefore have been unable to make a
decision to recommend vaccination or may have had poorer
health prevention behaviours or were less educated or required the
pupils to help at home. Sensitisation messages will need to be
specifically developed to reach older and poorer parents/
guardians, through community and religious leader engagement
in addition to standard approaches, and opportunities to answer
their questions will need to be provided prior to the start of
vaccination.
One potential life-experience that may have influenced vaccine
uptake concerned the national de-worming programme. Adverse
press coverage about reactions to praziquantel in Tanzania’s de-
worming programme in the mid-2000s led to public confusion and
concern about school-based health interventions, especially
vaccination, and impacted on the delivery of these programmes
[18]. Public memory of such events may be long, as demonstrated
by the loss in public confidence of oral poliovirus vaccine in
Nigeria and the measles-mumps-rubella (MMR) vaccine in the
United Kingdom [19,20]. In our study, girls who reported a non-
positive opinion about the national de-worming programmes in
schools were at high risk of failing to be vaccinated. Lack of trust in
this school health programme may have a significant impact on
the ultimate uptake of the HPV vaccine in schools unless this
concern is specifically addressed. Targeted messages should be
incorporated into sensitisation information to inform and reassure
parents and girls about both the benefits and safety of the de-
worming and the HPV vaccination programmes.
Reassuringly, no parents/guardians of cases raised the issue
that, because HPV vaccine was a vaccine against a sexually
transmitted disease, this would give girls a licence to have sex. This
concern has been raised by parents in some studies in developed
countries [15,21,22] although was not universally raised in other
studies [9,16].
Multiple studies have reported on the potential acceptability of
and barriers to HPV vaccination [11,14,21–29]. However
intention to accept an intervention does not necessarily translate
to actual acceptance. Strengths of our study include the fact that
we examined factors associated with failure to receive vaccine
during a vaccination programme, rather than a pre-intervention
assessment. We found some similarities to results from a study in
Scotland where girls were interviewed at the end of the three dose
course and reported concerns about vaccine safety and efficacy as
reasons for not being vaccinated [30]. Fear of side effects was an
important reason for non-uptake of vaccine in our study and has
been cited as a barrier to vaccination in a number of countries
[29,31–33]. This can substantially impact programmatic delivery
and uptake of vaccine, especially following potentially misleading
media coverage [34,35].
Prevention of cervical cancer was the primary reason given for
accepting the vaccine in both adults and girls. This is important
since research prior to vaccination in this population had shown
little or no knowledge about cervical cancer [16]. Interestingly
although peer-approval has been associated with vaccination in
the US [36], this was not cited as a reason for accepting
vaccination in our study.
Our study shows that it will be important to give parents and
pupils time to reconsider their decisions when a new national
vaccination programme commences. Most adults and pupils who
did not accept vaccination initially would have accepted this for
their daughters/themselves if they had been offered another
opportunity to do so. This could be achieved in practice by
offering several visits within a school year to receive dose 1,
making people aware during social mobilisation that it is
acceptable to change one’s mind about not accepting HPV
vaccination and then encouraging girls to inform the teachers or
health workers if they or their parents have reconsidered their
original decision not to receive vaccine.
Study limitations include potential selection bias. Only 60% of
cases participated in the study compared with more than 80% of
controls and therefore the interviewed cases may not be
representative of all vaccine non-receivers. However, since most
cases who did not participate were people who could no longer be
located, rather than actual refusals, the cases we did interview
should be representative of those girls who were still attending the
school but did not receive the HPV vaccine. We were not able to
separate out those who were absent because they stayed away to
avoid vaccination and those who absent for other reasons, and
these is evidence that these two groups are potentially different
since we did find some differences in parental education, how they
had learnt about HPV vaccine and in pupil age. Finally, adult
interviewees may not have been the primary decision maker in the
household at the time of vaccination and so may have guessed the
reasons behind the decision to receive or not receive vaccination
and all interviewees may have experienced recall bias since the
case-control study was done nearly a year after the first dose of
vaccine and they may not have recalled their original reasons for
refusing/accepting the vaccine.
In summary, sensitisation messages, retention of this knowledge
and parent meetings are critical for vaccine acceptance. Persistent
concerns about vaccine side effects and potential impact on fertility
will need to be closely addressed in a national vaccination
programme and steps will need to be taken to allow parents and
pupils who initially decline vaccination to reconsider their
decision.
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